{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35"}]}],"title":"Patient 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"147"}]}],"title":"Patient 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"38"}]}],"title":"Patient 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"184"}]}],"title":"Patient 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"66"}]}],"title":"Patient 5"}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"Time to initiation of cytotoxic chemotherapy will be defined as the time elapsed between study treatment initiation, and time of first non-targeted cytotoxic chemotherapy (off study treatment). Time to cytotoxic chemotherapy will be evaluated in all patients who receive at least one dose of study treatment.","groups":[{"description":"Induction:\n\n* Brentuximab vedotin 1.2 mg/kg IV infusion over 30 minutes, weekly x 3 (1 cycle = 4 weeks\n* Rituximab 375 mg/m2 IV infusion per standard protocol, once weekly for 4 weeks (1 cycle = 4 weeks)\n\nConsolidation (optional): Identical to Induction.\n\nMaintenance:\n\n* Brentuximab vedotin 1.8 mg/kg IV infusion over 30 minutes once every 3 weeks (1 cycle = 3 weeks), for a total of one year from the first induction dose or until progression of disease.\n* Rituximab 375 mg/m2 IV infusion per standard protocol, once every 6 weeks for a total of one year from the first induction dose or until progression of disease.","id":"OG000","title":"Brentuximb Vedotin Dose Level 1 (1.2 mg/kg)"}],"paramType":"NUMBER","populationDescription":"Follow-up data for time to initiation of cytotoxic chemotherapy was collected for only 5 patients. That data is reported below.","reportingStatus":"POSTED","timeFrame":"Up to 3 years from treatment discontinuation","title":"Time to Initiation of Cytotoxic Chemotherapy","type":"SECONDARY","unitOfMeasure":"number of days"}